Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1847094

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1847094

Fusion Proteins: Global Market

PUBLISHED:
PAGES: 127 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4650
PDF & Excel (2-5 Users)
USD 5580
PDF & Excel (Site License)
USD 6696
PDF & Excel (Enterprise License)
USD 8035

Add to Cart

The global market for fusion proteins is expected to grow from $36.3 billion in 2025 to reach $64.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030.

The North American market for fusion proteins is expected to grow from $13.3 billion in 2025 to reach $22.9 billion by the end of 2030, at a CAGR of 11.6% from 2025 to 2030.

The Asia-Pacific market for fusion proteins is expected to grow from $9 billion in 2025 to reach $17.6 billion by the end of 2030, at a CAGR of 14.5% from 2025 to 2030.

Report Scope

The report provides an overview of the global fusion proteins market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented based on type, route of administration, application and region.

According to type, the market is segmented into cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins and others. Based on application, the market is segmented into ophthalmic conditions, autoimmune diseases, metabolic disorders and hematological diseases. Regarding the route of administration, the market is segmented into intravenous, subcutaneous, intravitreal and others. The report also focuses on regional segmentation, including North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.

The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance developments and discusses pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section featuring company profiles with detailed information about leading companies. The scope of the report focuses on Fc-fusion protein products.

Report Includes

  • 92 data tables and 51 additional tables
  • An overview of the global market for fusion proteins (genetically engineered recombinant therapeutics)
  • Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
  • Estimates of the market size and revenue growth prospects, along with a corresponding market share analysis by ligand type, route of administration, application, and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
  • Impact analysis of U.S. tariff laws, as well as use cases of AI adoption on the fusion proteins market
  • Insights derived from Porter's Five Forces model, as well as global supply chain analyses
  • Information on emerging trends and applications in diagnostics and research industries, ongoing research activities, newly approved products, and underlying clinical trials
  • Identification of the major companies involved in the production and modification of fusion proteins, and analysis of the competitive landscape of the market
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • A relevant patent analysis, featuring key granted and published patents
  • Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
  • Profiles of the leading companies, including Regeneron Pharmaceuticals Inc., Bristol Myers Squibb Co., Lilly, Amgen Inc., and Sanofi
Product Code: BIO274A

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Technology Background
  • The Advantages of Fc-Fusion Proteins
  • Porter's Five Forces Analysis in the Fusion Proteins Market
  • Macroeconomic Factors Analysis
  • Impact of U.S. Tariffs
  • Government Policies on Drug Prices
  • Geopolitical Factors

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Need to Improve Pharmacokinetic and Pharmacodynamic Properties of Existing Protein Drugs
  • Demand for Targeted Therapeutics
  • Market Restraints
  • Manufacturing Challenges
  • Side Effects and Immunogenicity Risks
  • Market Opportunities
  • Diagnostic Applications of Fusion Proteins
  • Label Expansions and Drugs with Extended Duration

Chapter 4 Emerging Technologies and Pipeline Analysis

  • Key Takeaways
  • Emerging Technologies
  • Antibody-Directed Enzyme Prodrug Therapy
  • Artificial Intelligence for Fusion Protein Engineering
  • Bifunctional Fusion Proteins for Cancer Therapy
  • Pipeline Analysis

Chapter 5 Market Segmentation Analysis

  • Segmental Breakdown
  • Market Analysis by Ligand Type
  • Key Takeaways
  • Cytokine Traps
  • Peptide-Based Fusion Proteins
  • Receptor-Based Fusion Proteins
  • Others
  • Market Analysis by Route of Administration
  • Key Takeaways
  • Subcutaneous
  • Intravitreal
  • Intravenous
  • Others
  • Market Analysis by Application
  • Key Takeaways
  • Ophthalmic Conditions
  • Autoimmune Diseases
  • Metabolic Disorders
  • Hematological Diseases
  • Others
  • Geographic Breakdown
  • Market Analysis by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Key Takeaways
  • Industry Structure
  • Company Share Analysis of the Fusion Proteins Market
  • Strategic Analysis

Chapter 7 Sustainability in the Fusion Proteins Market: An ESG Perspective

  • Introduction to ESG
  • ESG Risk Ratings
  • Conclusion

Chapter 8 Appendix

  • Methodology
  • Sources
  • Acronyms
  • Company Profiles
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB CO.
  • EVIVE BIOTECH
  • F. HOFFMANN-LA ROCHE LTD.
  • KINIKSA PHARMACEUTICALS
  • LILLY USA LLC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • REMEGEN
  • SAMSUNG BIOEPIS
  • SANDOZ GROUP AG
  • SANOFI
  • Emerging Start-ups/Market Disruptors
Product Code: BIO274A

List of Tables

  • Summary Table : Global Fusion Proteins Market, by Region, Through 2030
  • Table 1 : Active Clinical Trials in the Fusion Proteins Industry, 2025
  • Table 2 : Global Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 3 : Global Cytokine Trap Fusion Proteins Market, by Region, Through 2030
  • Table 4 : Global Peptide-Based Fusion Proteins Market, by Region, Through 2030
  • Table 5 : Global Receptor-Based Fusion Proteins Market, by Region, Through 2030
  • Table 6 : Global Other Ligand Type Fusion Proteins Market, by Region, Through 2030
  • Table 7 : Global Fusion Proteins Market, by ROA, Through 2030
  • Table 8 : Global Fusion Proteins Market for Subcutaneous ROA, by Region, Through 2030
  • Table 9 : Global Fusion Proteins Market for Intravitreal ROA, by Region, Through 2030
  • Table 10 : Global Fusion Proteins Market for Intravenous ROA, by Region, Through 2030
  • Table 11 : Global Fusion Proteins Market for Other ROA, by Region, Through 2030
  • Table 12 : Global Fusion Proteins Market, by Application, Through 2030
  • Table 13 : Global Fusion Proteins Market for Ophthalmic Conditions, by Region, Through 2030
  • Table 14 : Global Fusion Proteins Market for Autoimmune Diseases, by Region,Through 2030
  • Table 15 : Global Fusion Proteins Market for Metabolic Disorders, by Region, Through 2030
  • Table 16 : Global Fusion Proteins Market for Hematological Diseases, by Region, Through 2030
  • Table 17 : Global Fusion Proteins Market for Other Applications, by Region, Through 2030
  • Table 18 : Global Fusion Proteins Market, by Region, Through 2030
  • Table 19 : North American Fusion Proteins Market, by Country, Through 2030
  • Table 20 : North American Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 21 : North American Fusion Proteins Market, by ROA, Through 2030
  • Table 22 : North American Fusion Proteins Market, by Application, Through 2030
  • Table 23 : U.S. Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 24 : U.S. Fusion Proteins Market, by ROA, Through 2030
  • Table 25 : U.S. Fusion Proteins Market, by Application, Through 2030
  • Table 26 : Canadian Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 27 : Canadian Fusion Proteins Market, by ROA, Through 2030
  • Table 28 : Canadian Fusion Proteins Market, by Application, Through 2030
  • Table 29 : Mexican Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 30 : Mexican Fusion Proteins Market, by ROA, Through 2030
  • Table 31 : Mexican Fusion Proteins Market, by Application, Through 2030
  • Table 32 : European Fusion Proteins Market, by Country, Through 2030
  • Table 33 : European Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 34 : European Fusion Proteins Market, by ROA, Through 2030
  • Table 35 : European Fusion Proteins Market, by Application, Through 2030
  • Table 36 : German Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 37 : German Fusion Proteins Market, by ROA, Through 2030
  • Table 38 : German Fusion Proteins Market, by Application, Through 2030
  • Table 39 : U.K. Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 40 : U.K. Fusion Proteins Market, by ROA, Through 2030
  • Table 41 : U.K. Fusion Proteins Market, by Application, Through 2030
  • Table 42 : French Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 43 : French Fusion Proteins Market, by ROA, Through 2030
  • Table 44 : French Fusion Proteins Market, by Application, Through 2030
  • Table 45 : Italian Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 46 : Italian Fusion Proteins Market, by ROA, Through 2030
  • Table 47 : Italian Fusion Proteins Market, by Application, Through 2030
  • Table 48 : Spanish Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 49 : Spanish Fusion Proteins Market, by ROA, Through 2030
  • Table 50 : Spanish Fusion Proteins Market, by Application, Through 2030
  • Table 51 : Rest of Europe Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 52 : Rest of Europe Fusion Proteins Market, by ROA, Through 2030
  • Table 53 : Rest of Europe Fusion Proteins Market, by Application, Through 2030
  • Table 54 : Asia-Pacific Fusion Proteins Market, by Country, Through 2030
  • Table 55 : Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 56 : Asia-Pacific Fusion Proteins Market, by ROA, Through 2030
  • Table 57 : Asia-Pacific Fusion Proteins Market, by Application, Through 2030
  • Table 58 : Chinese Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 59 : Chinese Fusion Proteins Market, by ROA, Through 2030
  • Table 60 : Chinese Fusion Proteins Market, by Application, Through 2030
  • Table 61 : Japanese Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 62 : Japanese Fusion Proteins Market, by ROA, Through 2030
  • Table 63 : Japanese Fusion Proteins Market, by Application, Through 2030
  • Table 64 : South Korean Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 65 : South Korean Fusion Proteins Market, by ROA, Through 2030
  • Table 66 : South Korean Fusion Proteins Market, by Application, Through 2030
  • Table 67 : Indian Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 68 : Indian Fusion Proteins Market, by ROA, Through 2030
  • Table 69 : Indian Fusion Proteins Market, by Application, Through 2030
  • Table 70 : Australian Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 71 : Australian Fusion Proteins Market, by ROA, Through 2030
  • Table 72 : Australian Fusion Proteins Market, by Application, Through 2030
  • Table 73 : Rest of Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 74 : Rest of Asia-Pacific Fusion Proteins Market, by ROA, Through 2030
  • Table 75 : Rest of Asia-Pacific Fusion Proteins Market, by Application, Through 2030
  • Table 76 : RoW Fusion Proteins Market, by Subregion, Through 2030
  • Table 77 : RoW Fusion Proteins Market, by Ligand Type, Through 2030
  • Table 78 : RoW Fusion Proteins Market, by ROA, Through 2030
  • Table 79 : RoW Fusion Proteins Market, by Application, Through 2030
  • Table 80 : Recent Developments in the Fusion Proteins Market, 2022-2025
  • Table 81 : ESG Risk Rankings for Fusion Protein Drugs Companies, 2025
  • Table 82 : Report Information Sources
  • Table 83 : Abbreviations Used in the Global Fusion Proteins Market
  • Table 84 : Amgen Inc.: Company Snapshot
  • Table 85 : Amgen Inc.: Financial Performance, FY 2023 and 2024
  • Table 86 : Amgen Inc.: Product Portfolio
  • Table 87 : Amgen Inc.: News/Key Developments, 2022-2025
  • Table 88 : AstraZeneca: Company Snapshot
  • Table 89 : AstraZeneca: Financial Performance, FY 2023 and 2024
  • Table 90 : AstraZeneca: Product Portfolio
  • Table 91 : AstraZeneca: News/Recent Developments, 2023
  • Table 92 : Bayer AG: Company Snapshot
  • Table 93 : Bayer AG: Financial Performance, FY 2023 and 2024
  • Table 94 : Bayer AG: Product Portfolio
  • Table 95 : Bayer AG: News/Recent Developments, 2025
  • Table 96 : Bristol-Myers Squibb Co.: Company Snapshot
  • Table 97 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
  • Table 98 : Bristol-Myers Squibb Co.: Product Portfolio
  • Table 99 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
  • Table 100 : Evive Biotech: Company Snapshot
  • Table 101 : Evive Biotech: Product Portfolio
  • Table 102 : Evive Biotech: News/Key Developments, 2024-2025
  • Table 103 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 104 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
  • Table 105 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 106 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
  • Table 107 : Kiniksa Pharmaceuticals: Company Snapshot
  • Table 108 : Kiniksa Pharmaceuticals: Financial Performance, FY 2023 and 2024
  • Table 109 : Kiniksa Pharmaceuticals: Product Portfolio
  • Table 110 : Kiniksa Pharmaceuticals: News/Key Developments, 2022
  • Table 111 : Lilly USA LLC.: Company Snapshot
  • Table 112 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
  • Table 113 : Lilly USA LLC.: Product Portfolio
  • Table 114 : Lilly USA LLC.: News/Key Developments, 2025
  • Table 115 : Merck & Co. Inc.: Company Snapshot
  • Table 116 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
  • Table 117 : Merck & Co. Inc.: Product Portfolio
  • Table 118 : Merck & Co. Inc.: News/Key Developments, 2023
  • Table 119 : Pfizer Inc.: Company Snapshot
  • Table 120 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
  • Table 121 : Pfizer Inc.: Product Portfolio
  • Table 122 : Pfizer Inc.: News/Key Developments, 2022
  • Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
  • Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
  • Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
  • Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
  • Table 127 : RemeGen: Company Snapshot
  • Table 128 : RemeGen: Financial Performance, FY 2023 and 2024
  • Table 129 : RemeGen: Product Portfolio
  • Table 130 : RemeGen: News/Key Developments, 2025
  • Table 131 : Samsung Bioepis: Company Snapshot
  • Table 132 : Samsung Bioepis: Product Portfolio
  • Table 133 : Samsung Bioepis: News/Key Developments, 2025
  • Table 134 : Sandoz Group AG: Company Snapshot
  • Table 135 : Sandoz Group AG: Financial Performance, FY 2023 and 2024
  • Table 136 : Sandoz Group AG: Product Portfolio
  • Table 137 : Sandoz Group AG: News/Key Developments, 2025
  • Table 138 : Sanofi: Company Snapshot
  • Table 139 : Sanofi: Financial Performance, FY 2023 and 2024
  • Table 140 : Sanofi: Product Portfolio
  • Table 141 : Sanofi: News/Key Developments, 2024
  • Table 142 : List of a Few Emerging Startups

List of Figures

  • Summary Figure : Global Market Shares of Fusion Proteins, by Region, 2024
  • Figure 1 : Characteristics of Therapeutic Fusion Proteins
  • Figure 2 : Porter's Five Forces Analysis: Fusion Proteins Market
  • Figure 3 : Global Market Dynamics of Fusion Proteins
  • Figure 4 : Emerging Technologies in the Fusion Proteins Market
  • Figure 5 : Global Market Shares of Fusion Proteins, by Ligand Type, 2024
  • Figure 6 : Global Market Shares of Fusion Proteins, by ROA, 2024
  • Figure 7 : Global Market Shares of Fusion Proteins, by Application, 2024
  • Figure 8 : Global Market Shares of Fusion Proteins, by Region, 2024
  • Figure 9 : North American Market Shares of Fusion Proteins, by Country, 2024
  • Figure 10 : European Market Shares of Fusion Proteins, by Country, 2024
  • Figure 11 : Asia-Pacific Market Shares of Fusion Proteins, by Country, 2024
  • Figure 12 : RoW Market Shares of Fusion Proteins, by Subregion, 2024
  • Figure 13 : Global Fusion Proteins Market Share Analysis, by Company, 2024
  • Figure 14 : Key ESG Metrics of Fusion Proteins Companies
  • Figure 15 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 16 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 17 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
  • Figure 18 : AstraZeneca: Revenue Share, by Country/Region, FY 2024
  • Figure 19 : Bayer AG: Revenue Share, by Business Unit, FY 2024
  • Figure 20 : Bayer AG: Revenue Share, by Country/Region, FY 2024
  • Figure 21 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
  • Figure 22 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
  • Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
  • Figure 24 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
  • Figure 25 : Kiniksa Pharmaceuticals: Revenue Share, by Business Unit, FY 2024
  • Figure 26 : Lilly USA LLC.: Revenue Share, by Business Unit, FY 2024
  • Figure 27 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
  • Figure 28 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 29 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 30 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 31 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 32 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 33 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 34 : RemeGen: Revenue Share, by Country/Region, FY 2024
  • Figure 35 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024
  • Figure 36 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024
  • Figure 37 : Sanofi: Revenue Share, by Country/Region, FY 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!